Des mutations de KRAS aux mutations de RAS : vers une meilleure définition de la réponse aux anticorps anti-EGFR dans le cancer colorectal métastatique
作者： A. Lièvre
DOI: 10.1007/S10269-014-2376-4
关键词: Neuroblastoma RAS viral oncogene homolog 、 Medicine 、 KRAS 、 Molecular biology
摘要: L’identification des mutations de KRAS comme facteur predictif resistance aux anticorps anti-EGFR a permis faire un grand pas dans la personnalisation du traitement cancer colorectal metastatique. Recemment, recherche d’autres au niveau genes famille RAS fait preuve son interet l’identification patients pouvant tirer benefice ces anti-EGFR. Parallelement, travaux plus fondamentaux ont mieux comprendre les mecanismes secondaire et d’envisager, court ou moyen terme, sang peripherique.
springer.com
sci-hub.se 参考文章(41)
Ligue contre le cancer Comité de la Corrèze, Institut National du Cancer ,(2012)
Malachi Griffith, Obi L. Griffith, COSMIC (Catalogue of Somatic Mutations in Cancer) Dictionary of Bioinformatics and Computational Biology. ,(2004) , 10.1002/9780471650126.DOB0851
Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Ursula Vehling-Kaiser, Salah-Eddin Al-Batran, Tobias Heintges, Juergen Lerchenmueller, Christoph Kahl, Gernot Seipelt, Frank Kullmann, Martina Stauch, Werner Scheithauer, Joerg Hielscher, Michael Scholz, Sebastian Mueller, Britta Schaefer, Dominik Paul Modest, Andreas Jung, Sebastian Stintzing, Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS-wildtype metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3). Journal of Clinical Oncology. ,vol. 31, ,(2013) , 10.1200/JCO.2013.31.15_SUPPL.LBA3506
J. Metges, J. Raoul, N. Achour, O. Capitain, A. Gourlaouen, J. Ramée, J. Egreteau, J. Douillard, S. Traoré, F. Grudé, PANERB study: Panitumumab after cetuximab-based regimen failure. Journal of Clinical Oncology. ,vol. 28, ,(2010) , 10.1200/JCO.2010.28.15_SUPPL.E14000
Claudia Esposito, Anna Maria Rachiglio, Maria Libera La Porta, Alessandra Sacco, Cristin Roma, Alessia Iannaccone, Fabiana Tatangelo, Laura Forgione, Raffaella Pasquale, Americo Barbaro, Gerardo Botti, Fortunato Ciardiello, Nicola Normanno, The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies. Cancer Biology & Therapy. ,vol. 14, pp. 1143- 1146 ,(2013) , 10.4161/CBT.26340
Fernando Rivera, Meinolf Karthaus, Gianpiero Fasola, Jean-Luc Canon, Lee Schwartzberg, Hua Yu, Kelly Oliner, William Go, O-0013KRAS/NRAS MUTATIONS IN PEAK: A RANDOMIZED PHASE 2 STUDY OF 1ST-LINE TREATMENT WITH FOLFOX6 + PANITUMUMAB OR BEVACIZUMAB FOR WILD-TYPE KRAS MCRC Annals of Oncology. ,vol. 24, ,(2013) , 10.1093/ANNONC/MDT201.13
Zheng Jiang, Chunxiang Li, Fuyuan Li, Xishan Wang, EGFR Gene Copy Number as a Prognostic Marker in Colorectal Cancer Patients Treated with Cetuximab or Panitumumab: A Systematic Review and Meta Analysis PLoS ONE. ,vol. 8, pp. e56205- ,(2013) , 10.1371/JOURNAL.PONE.0056205
F Di Fiore, F Blanchard, F Charbonnier, F Le Pessot, A Lamy, M P Galais, L Bastit, A Killian, R Sesboüé, J J Tuech, A M Queuniet, B Paillot, J C Sabourin, F Michot, P Michel, T Frebourg, Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. British Journal of Cancer. ,vol. 96, pp. 1166- 1169 ,(2007) , 10.1038/SJ.BJC.6603685
Clara Montagut, Alba Dalmases, Beatriz Bellosillo, Marta Crespo, Silvia Pairet, Mar Iglesias, Marta Salido, Manuel Gallen, Scot Marsters, Siao Ping Tsai, André Minoche, Somasekar Seshagiri, Sergi Serrano, Heinz Himmelbauer, Joaquim Bellmunt, Ana Rovira, Jeff Settleman, Francesc Bosch, Joan Albanell, Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer Nature Medicine. ,vol. 18, pp. 221- 223 ,(2012) , 10.1038/NM.2609
Alberto Bardelli, Salvatore Siena, Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer Journal of Clinical Oncology. ,vol. 28, pp. 1254- 1261 ,(2010) , 10.1200/JCO.2009.24.6116